IMBcom is committed
to the development of technologies through the establishment of
a series of spin-off and start-up companies to facilitate and foster
the development of a region committed to the establishment of a
biotechnology industry. Over the past five years, IMBcom has been actively involved in creating several startup companies with a particular focus on human therapeutics and relevant technologies:
- Xenome Ltd
- Promics Pty Ltd
- Protagonist Pty Ltd
- Mimetica Pty Ltd
- Nanomics Pty Ltd
- Kalthera Pty Ltd
- Cyclagen Pty Ltd
- Nephrogenix Pty Ltd
- ElaCor Pty Ltd
Click on the links below to find out more about these companies.
Ltd is a world leader in the discovery of novel peptides from animal venoms. Formed as a spin-off Company from ground-breaking research conducted at the University of Queensland, Xenome has generated a unique expertise in peptide chemistry to enable the production of a library of molecules from venoms that is now in demand by international biotechnology and pharmaceutical companies. Peptides with unique chemistry and pharmacology are being used in Xenome's drug development activities that are focused on pain management, urological disorders, airway disorders and diseases of the central nervous system. Currently the major shareholder of the company is Queensland BioCapital Fund (QBF), a wholly owned subsidiary of the Queensland Investment Corporation.
Promics Pty Ltd creates cyclical peptides that reproduce or mimic secondary
structural characteristics of proteins to make therapeutic compounds
with focus on the Complement Cascade / Inflammatory diseases.
Pty Ltd was established to develop and commercialise C5a antagonist
drug leads and associated technology. The company was formed following
a venture capital investment by GBS Venture Partners (previously
Rothschild Bioscience) and Start-up Australia in December 1999.
The company is currently proceeding with Phase Ib/IIa and Phase IIa human
Pty Ltd is building an international business dedicated to the
discovery of small molecules that mimic or inhibit protein-protein
approach is to combine protein structural information with combinatorial
chemistry, resulting in the design and synthesis of molecules that
mimic protein structure, ultimately leading to the discovery of
compounds that mimic protein function.
has already designed and synthesised several series of molecules
that modulate targets previously resistant to small molecule discovery.
Protagonist plans to optimise these compounds and seek alliances
to apply its platform technology to targets of interest to partners.The
company will also develop its lead compounds in partnership with
Pty Ltd was formed to exploit a chemical technology for creating
drug candidates directly from the known structures of† natural peptides,
proteins and related compounds. These "peptide mimetics" are based
on a variety of proprietary chemical scaffolds developed by the
was awarded a Queensland State Government BioStart grant in 2001
and has completed negotiations for first round venture capital funding.
An overview of the Mimetica technology will be online soon.
Biosystems Pty Ltd is a biotechnology company focused on commercialising
a versatile platform technology spanning the fields of genomics,
proteomics, drug discovery, and human diagnostics. The novel technology
provides a method of barcoding libraries of tiny ceramic beads with
labels to create unique optical signatures and hence the ability
to track individual chemicals attached to their surfaces. Nanomics
revolutionary "colloidal barcoding" approach will, for the first
time, make available massive libraries of identifiable chemical
entities that can be economically and easily utilized for a variety
of tasks including DNA sequencing, SNP analysis discovery, gene
expression analysis, drug discovery, pharmacogenomics, diagnostics
and therapeutics. The unique versatility of Nanomics technology
facilitates entry into a number of markets from gene expression
analysis and drug discovery to personalised medical treatment.
Pty Ltd strives to provide solutions for problematic peptide drugs, accessing and extending the lucrative protein therapeutics market. The technology provides a means to combine the potency and specificity of a peptide with the potential to gain the stability and bioavailability of a small molecule. This is based on Cyclic Cystine Knot (CCK) peptides which can be manipulated through two parallel pathways for development. The first, Frameworks Technology, provides the opportunity for grafting desired bioactivities into a well characterized pharmaceutically optimized framework, enabling streamlined development and stabilized delivery. The second, Cyclisation Technology, involves the cyclisation of existing peptide leads to confer stability. Kalthera Pty Ltd is currently pursuing partners with peptide leads and development candidates.
has discovered a natural, novel system that many plants appear to utilize for protection against insect attack. This system is based on a unique class of proteins that have a novel structural framework called the Cyclic Cystine Knot (CCK). The proteins display a range of unique characteristics, including potent insecticidal and microbial activity. Cyclagen has characterised a large number of these proteins and potent insecticidal activities have been demonstrated. They appear to affect a novel spectrum of insects and have a marked effect on the growth and mortality of the global pest Helicoverpa spp. The efficacy of this system is currently being demonstrated in a range of transgenic plants. Cyclagen is pursuing technology development and field trials in crops, forestry and horticultural applications.
Pty Ltd is actively developing cell based therapies for renal disease. Nephrogenix draws on the collective research efforts of some of Australia's pre-eminent researchers at The University of Queensland and Monash University in the fields of cell and tissue based therapies and kidney development to develop the next generation renal treatments. Nephrogenix is positioned to become the leading biotech company for the commercialisation of novel methodologies, cellular therapies, and therapeutics in renal regeneration.
Pty Ltd is developing a technology based on the discovery of a group of novel natriuretic peptides isolated from Taipan snake venom. The lead compound, characterised by high potency, remarkable stability and lack of side-effects holds great promise as a therapeutic for congestive heart failure. The company aims to produce a superstable derivative based on the lead compound suitable for clinical development.